Abstract: A method of treating a disease associated with a cell population which proliferates abnormally in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one modulator capable of modulating in the cell population a level and/or activity of a polypeptide having an amino acid sequence at least 60 percent similar to SEQ ID NO: 5, as determined using the Standard protein-protein BLAST [blastp] software of the NCBI.

Abstract: A system and method is provided for magnetic resonance angiography (MRA) that includes performing a pulse sequence using the MRI system, the pulse sequence including a phase-based flow encoding to collect a time-series of image data from the portion of the vasculature of the subject and identifying at least a portion of the time series of image data corresponding to a period of reduced flow through the portion of the vasculature. The portion of the time series of image data is subtracted from the time series of image data to create a time series of images of the portion of the vasculature having background tissue surrounding the portion of the vasculature substantially suppressed.

Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).

Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.

Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).

Abstract: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.

Abstract: A solution for managing messaging is provided in which an event related to a publisher is identified. In response to the event, a transaction is initiated for processing the event, the event is processed within the transaction, and the transaction is committed after the event is processed. During processing, data corresponding to the event is provided for use by a set of subscribers to the event, and data related to the set of subscribers is identified. In an embodiment, a message broker in a publication and subscribe messaging environment implements the solution in order to be capable of providing the data related to the set of subscribers to the publisher. Use of the transaction ensures that the data related to the set of subscribers accurately represents the set of subscribers at the time that the data corresponding to the event was provided.

Abstract: Provided herein, inter alia, are novel compounds for the inhibition of HIV integrase. The compounds disclosed herein are useful for methods of treating HIV infection in a subject in need thereof.

Abstract: This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding ?2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.

Abstract: The present invention relates to novel recombinant polypeptide antigens that may comprise subunit vaccines against rotavirus infection. Further, the present invention relates to methods for use of said antigens in the diagnosis, treatment and prevention of rotavirus infection.

Abstract: An example embodiment relates to a method of manufacturing an array of electric devices that includes attaching a platform including a micro-channel structure to a substrate. The method includes injecting first and second solutions into the micro-channel structure to form at least three liquid film columns, where the first and second solutions include different solvent composition ratios and the liquid columns each, respectfully, include different solvent composition ratios. The method further includes detaching the platform the substrate, removing solvent from the liquid film columns to form thin film columns, and treating the thin film columns under different conditions along a length direction of the thin film columns. The solvent is removed from the thin film columns and the thin film columns are treated under different conditions along a length direction of the thin film columns.

Abstract: A reconstructed image is rendered from a set of MRI data by first estimating an image with an area which does not contain artifacts or has an artifact with a relative small magnitude. Corresponding data elements in the estimated image and a trial image are processed, for instance by multiplication, to generate an intermediate data set. The intermediate data set is transformed and minimized iteratively to generate a reconstructed image that is free or substantially free of artifacts. In one embodiment a Karhunen-Loeve Transform (KLT) is used. A sparsifying transformation may be applied to generate the reconstructed image. The sparsifying transformation may be also not be applied.

Abstract: The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.

Abstract: Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided.

Abstract: An acoustical fluid control mechanism and a method of controlling fluid flow of a working fluid with the acoustical fluid control mechanism are provided. The mechanism comprises a resonance chamber that defines a cavity. The resonance chamber has a port. The cavity is sealed from the ambient but for the port for enabling oscillatory flow of a working fluid into and out of the cavity upon exposure of the resonance chamber to an acoustic signal containing a tone at a frequency that is substantially similar to a particular resonance frequency of the resonance chamber. The mechanism further includes a rectifier for introducing directional bias to the oscillatory flow of the working fluid through the port. The rectifier has an inlet connected to the port and an outlet for transmitting the directional flow of the working fluid away from the cavity. The outlet is in fluid communication with the port of the resonance chamber at least during transmission of the directional flow of the working fluid therethrough.

Abstract: Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent Chlamydia-associated or induced rheumatoid arthritis.

Abstract: Techniques include performing text mining on a set of case reports in text format to determine a set of grammar rules to be used to determine whether case reports meet a medical condition. The text mining includes performing feature selection, used to determine the set of grammar rules, that combines standardized case definitions with experience of medical officers for the medical condition and outputting the set of grammar rules. Another technique includes applying grammar rule(s) to new case report(s), the grammar rule(s) previously determined at least by performing text mining comprised of performing feature selection, used to determine the set of grammar rules, that combines standardized case definitions with experience of medical officers for the medical condition. Indication(s) are output of whether the new case report(s) meet or do not meet the medical condition. The techniques may be performed by a method, an apparatus, and a program product.

Abstract: Method, system, and computer program method for detecting pathological fluctuations of physiological signals to diagnose human illness. The method comprises performing a sliding window analysis to find sequences in physiological signal data that match amplitude- and duration-adjusted versions of a template function to within a specified tolerance.

Abstract: Systems and methods are disclosed for directing magnetizable particles comprising therapeutic agents to a target volume, or for guiding magnetizable particles comprising therapeutic agents from a first target volume to a second target volume, at a distance using a magnetic field, to enable the treatment of diseased areas including areas deep inside a patient's body. The methods may be used to diagnose or treat diseased areas within a patient, for example tumors of the lungs, intestines, and liver, and is also useful in enhancing the permeability of solid tumors to chemotherapeutic agents.

Abstract: Phase sensitive T1 mapping is provided in magnetic resonance (MR). The phase from samples of a modified Look-Locker inversion recovery sequence may be used to normalize contrast, allowing for accurate motion registration without extra information acquisition. The sign may be estimated, allowing T1 mapping with a single application of a non-linear fit.